ETV6-NTRK3 is the defining fusion of mammary analogue secretory carcinoma (MASC) of saliv...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BMA-NTRK-ETV6-SALIVARY |
|---|---|
| Type | Actionability |
| Status | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Diseases | DIS-SALIVARY |
| Sources | SRC-FDA-CDS-2026 |
Actionability Facts
| Biomarker | BIO-NTRK-FUSION |
|---|---|
| Variant | ETV6-NTRK3 fusion |
| Disease | DIS-SALIVARY |
| ESCAT tier | IA |
| Recommended combinations | larotrectinib monotherapy, entrectinib monotherapy |
| Evidence summary | ETV6-NTRK3 is the defining fusion of mammary analogue secretory carcinoma (MASC) of salivary gland. Larotrectinib and entrectinib are highly active (NAVIGATE / STARTRK-2 pooled — ORR 75-90% in salivary cohort). Treatment is identical to gene-level NTRK fusion. |
Notes
ESCAT IA. OncoKB Level 1. Fusion-partner-specific cell maintained for completeness. ETV6-NTRK3 also drives infantile fibrosarcoma, congenital mesoblastic nephroma, and a fraction of secretory breast carcinoma — separate BMA cells per disease.
Used By
No reverse references found in the YAML corpus.